Phase III Study to Evaluate the Efficacy and Safety of AD-209

Addpharma

Status and phase: Enrolling; Phase 3

Conditions: Hypertension,Essential

Treatments: Drug: AD-2091 Placebo; Drug: AD-209; Drug: AD-2091; Drug: AD-209 Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06348576

AD-209P3

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of AD-209

Full description

Condition or disease : hypertension

Enrollment: 280 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Other inclusions applied

Exclusion criteria

• Orthostatic hypotension with symptom
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

280 participants in 2 patient groups

Test group

Experimental group

Description:

AD-209+AD-2091 Placebo

Treatment:

Drug: AD-209

Drug: AD-2091 Placebo

Control group

Active Comparator group

Description:

AD-2091+AD-209 Placebo

Treatment:

Drug: AD-2091

Drug: AD-209 Placebo